2021
Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study.
Howell J, Samani A, Mannan B, Hajiev S, Aval L, Abdelmalak R, Tam V, Bettinger D, Thimme R, Taddei T, Kaplan D, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study. Journal Of Clinical Oncology 2021, 39: 289-289. DOI: 10.1200/jco.2021.39.3_suppl.289.Peer-Reviewed Original ResearchImpact of NAFLDOverall survivalHepatocellular carcinomaLiver diseaseNon-alcoholic fatty liver diseaseMultivariable Cox proportional hazardsAdvanced-stage hepatocellular carcinomaLower starting doseSorafenib-related toxicityFatty liver diseaseStage hepatocellular carcinomaCox proportional hazardsLogistic regression modellingStarting doseMedian BMIPrognostic factorsSpecialist centresHCC patientsNAFLDTreatment responseInternational cohortPatientsSorafenibDemographic dataSurvival
2020
An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib.
Sharma R, Hajiev S, Aval L, Bettinger D, Arizumi T, Pirisi M, Rimassa L, Personeni N, Pressiani T, Giordano L, Kudo M, Thimme R, Park J, Taddei T, Kaplan D, Ramaswami R, Pinato D, Allara E. An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib. Journal Of Clinical Oncology 2020, 38: 12049-12049. DOI: 10.1200/jco.2020.38.15_suppl.12049.Peer-Reviewed Original ResearchOverall survivalStarting doseHepatocellular carcinomaAdvanced-stage hepatocellular carcinomaLower starting doseSorafenib-related toxicityMedian overall survivalMulticentre cohort studyPortal vein thrombosisTerms of OSLow-dose therapyDose of sorafenibRates of toxicitySorafenib dosingSorafenib toxicityChild-PughDose therapyCohort studyElderly patientsOlder patientsVein thrombosisClinical efficacySimilar incidenceSpecialist centresLarge tumors